Suppr超能文献

在汇集样本检测 SARS-CoV-2 时,对阳性结果进行特征描述的复杂性。

Intricacies in characterizing positivity in pooled sample testing for SARS-CoV-2.

机构信息

Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.

出版信息

J Med Virol. 2021 May;93(5):2799-2804. doi: 10.1002/jmv.26618. Epub 2021 Feb 23.

Abstract

The unprecedented demand for testing for the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 has led to an acute shortage and limited availability of test reagents for which pooling of samples has been recommended in areas with low prevalence. Considering the possibility of dilution factor in pool testing, an attempt was made to find out possibility of any true positive samples in pools with late amplification. The study was conducted on samples received from various collection centers in different districts of Odisha as well as from patients attending the screening clinic or admitted in COVID ward of the hospital. Nasal/nasopharyngeal/throat swabs received in viral transport media in cold chain were subjected to Real-time polymerase chain reaction (RT-PCR) testing in a Biosafety Laboratory level-2 by including uniform volume of four units (samples) per pool. All confirmed and probable positive pools in screening assay were de-convoluted and individual samples tested for confirmatory assay. Inclusion of an additional criteria of probable positive pool (C value >35 with non-sigmoid amplification curve or showing a line of amplification towards the end of the cycle) yielded 39 (15.5%) more true positive samples out of a total of 251 positive samples that would otherwise have been missed if only the classical criteria of positive (C within 35 with proper sigmoid curve) had been considered. The study highlights the importance of considering any indication of late amplification in the RT-PCR test to label a pool as positive to avoid missing any true positive sample in the pool.

摘要

由于严重急性呼吸综合征冠状病毒 2 引起的持续的 2019 年冠状病毒病(COVID-19)大流行对检测的需求空前,导致测试试剂出现严重短缺和供应有限,因此在低流行地区推荐对样本进行混合。考虑到池检测中可能存在稀释因素,我们试图找出在晚期扩增的池中有任何真正阳性样本的可能性。该研究在奥里萨邦不同地区的各个收集中心收到的样本以及在筛查诊所就诊或在医院 COVID 病房住院的患者中进行。在冷链中用病毒运输培养基接收的鼻/鼻咽/咽喉拭子在生物安全实验室 2 级通过包括每个池四个单位(样本)的均匀体积进行实时聚合酶链反应(RT-PCR)测试。在筛查检测中,对所有确证和可能阳性的池进行解卷积,并对每个样本进行确认检测。如果仅考虑经典的阳性标准(C 值在 35 以内,具有适当的 S 型曲线),那么除了确证阳性池的另一个标准(C 值>35,非 S 型扩增曲线或在循环结束时显示扩增线)外,还可以从总共 251 个阳性样本中额外获得 39 个(15.5%)真正的阳性样本,否则这些样本可能会被遗漏。该研究强调了在 RT-PCR 测试中考虑任何晚期扩增迹象的重要性,以将池标记为阳性,从而避免在池中遗漏任何真正的阳性样本。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验